These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 17652812)

  • 1. Antioxidant defense against anthracycline cardiotoxicity by metallothionein.
    Kang YJ
    Cardiovasc Toxicol; 2007; 7(2):95-100. PubMed ID: 17652812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel antioxidants in anthracycline cardiotoxicity.
    Hideg K; Kálai T
    Cardiovasc Toxicol; 2007; 7(2):160-4. PubMed ID: 17652823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of cytochrome C oxidase-va is possibly involved in metallothionein protection from doxorubicin cardiotoxicity.
    Merten KE; Feng W; Zhang L; Pierce W; Cai J; Klein JB; Kang YJ
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1314-9. PubMed ID: 16144979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New iron chelators in anthracycline-induced cardiotoxicity.
    Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
    Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials.
    Bast A; Haenen GR; Bruynzeel AM; Van der Vijgh WJ
    Cardiovasc Toxicol; 2007; 7(2):154-9. PubMed ID: 17652822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart.
    Sun X; Zhou Z; Kang YJ
    Cancer Res; 2001 Apr; 61(8):3382-7. PubMed ID: 11309296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zinc, antioxidant systems and metallothionein in metal mediated-apoptosis: biochemical and cytochemical aspects.
    Formigari A; Irato P; Santon A
    Comp Biochem Physiol C Toxicol Pharmacol; 2007 Nov; 146(4):443-59. PubMed ID: 17716951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II-induced p53-dependent cardiac apoptotic cell death: its prevention by metallothionein.
    Liu Q; Wang G; Zhou G; Tan Y; Wang X; Wei W; Liu L; Xue W; Feng W; Cai L
    Toxicol Lett; 2009 Dec; 191(2-3):314-20. PubMed ID: 19808082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.
    Menna P; Salvatorelli E; Minotti G
    Chem Res Toxicol; 2010 Jan; 23(1):6-10. PubMed ID: 19954191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metallothionein protects against doxorubicin-induced cardiomyopathy through inhibition of superoxide generation and related nitrosative impairment.
    Shuai Y; Guo JB; Peng SQ; Zhang LS; Guo J; Han G; Dong YS
    Toxicol Lett; 2007 Apr; 170(1):66-74. PubMed ID: 17382496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
    Menna P; Salvatorelli E; Minotti G
    Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgenic mice overexpressing metallothionein are not resistant to adriamycin cardiotoxicity.
    DiSilvestro RA; Liu J; Klaassen CD
    Res Commun Mol Pathol Pharmacol; 1996 Aug; 93(2):163-70. PubMed ID: 8884987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoprotective agents for anthracyclines.
    Dorr RT
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):23-34. PubMed ID: 8783663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
    Langer SW; Jensen PB; Sehested M
    Cardiovasc Toxicol; 2007; 7(2):151-3. PubMed ID: 17652821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening of antioxidants from medicinal plants for cardioprotective effect against doxorubicin toxicity.
    Wattanapitayakul SK; Chularojmontri L; Herunsalee A; Charuchongkolwongse S; Niumsakul S; Bauer JA
    Basic Clin Pharmacol Toxicol; 2005 Jan; 96(1):80-7. PubMed ID: 15667600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling.
    Li L; Pan Q; Han W; Liu Z; Li L; Hu X
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6753-60. PubMed ID: 18006777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways.
    Jirkovsky E; Popelová O; Kriváková-Stanková P; Vávrová A; Hroch M; Hasková P; Brcáková-Dolezelová E; Micuda S; Adamcová M; Simůnek T; Cervinková Z; Gersl V; Sterba M
    J Pharmacol Exp Ther; 2012 Nov; 343(2):468-78. PubMed ID: 22915767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.
    Jirkovský E; Lenčová-Popelová O; Hroch M; Adamcová M; Mazurová Y; Vávrová J; Mičuda S; Šimůnek T; Geršl V; Štěrba M
    Toxicology; 2013 Sep; 311(3):191-204. PubMed ID: 23831762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis of anthracycline-induced cardiotoxicity and its prevention.
    Horenstein MS; Vander Heide RS; L'Ecuyer TJ
    Mol Genet Metab; 2000; 71(1-2):436-44. PubMed ID: 11001837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
    Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.